By Chris Wack

Pfizer Inc. (PFE) and Eli Lilly and Co. (LLY) said Wednesday that a 16-week Phase 3 study in patients with osteoarthritis pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints.

The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients' overall assessment of their osteoarthritis, compared to those receiving a placebo, the drug companies in a release.

"We are encouraged by these results, which speak to the potential of tanezumab as a non-opioid treatment option for pain reduction and improvement in physical function in people living with osteoarthritis pain," Pfizer's Ken Verburg said.

Preliminary safety data showed that tanezumab was generally well tolerated, with about 1% of patients discontinuing treatment due to adverse events.

Pfizer and Lilly received U.S. Food and Drug Administration Fast Track designation for tanezumab for the treatment of osteoarthritis pain and chronic lower back pain in June 2017.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 18, 2018 07:28 ET (11:28 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Pfizer
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Pfizer